Haznedar J - Search Results

1

Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.

Patyna S, Haznedar J, Morris D, Freshwater K, Peng G, Sukbuntherng J, Chmielewski G, Matsumoto D. Patyna S, et al. Among authors: haznedar j. Birth Defects Res B Dev Reprod Toxicol. 2009 Jun;86(3):204-13. doi: 10.1002/bdrb.20194. Birth Defects Res B Dev Reprod Toxicol. 2009. PMID: 19294680

2

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D. Patyna S, et al. Among authors: haznedar jo. Mol Cancer Ther. 2006 Jul;5(7):1774-82. doi: 10.1158/1535-7163.MCT-05-0333. Mol Cancer Ther. 2006. PMID: 16891463

3

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.

Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L, Wu EY. Haznedar JO, et al. Cancer Chemother Pharmacol. 2009 Sep;64(4):691-706. doi: 10.1007/s00280-008-0917-1. Epub 2009 Jan 25. Cancer Chemother Pharmacol. 2009. PMID: 19169880

4

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. Mendel DB, et al. Among authors: haznedar jo. Clin Cancer Res. 2003 Jan;9(1):327-37. Clin Cancer Res. 2003. PMID: 12538485

5

Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS.

Zhao Y, Yang CY, Haznedar J, Antonian L. Zhao Y, et al. Among authors: haznedar j. J Pharm Biomed Anal. 2001 Jul;25(5-6):821-32. doi: 10.1016/s0731-7085(01)00341-7. J Pharm Biomed Anal. 2001. PMID: 11377065

6

Single-dose pharmacokinetics of the HCV polymerase inhibitor mericitabine in healthy Caucasian and Japanese subjects.

Washington C, Moreira S, Haznedar J, Goelzer P, Chen YC. Washington C, et al. Among authors: haznedar j. Drug Metab Pharmacokinet. 2014;29(2):141-7. doi: 10.2133/dmpk.dmpk-13-rg-016. Epub 2013 Sep 10. Drug Metab Pharmacokinet. 2014. PMID: 24025983 Free article. Clinical Trial.

7

Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.

Reddy MB, Chen Y, Haznedar JO, Fretland J, Blotner S, Smith P, Tran JQ. Reddy MB, et al. Among authors: haznedar jo. Clin Pharmacokinet. 2012 Jul 1;51(7):457-65. doi: 10.2165/11599700-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22624502 Clinical Trial.

8

Evaluation of the effect of mericitabine at projected therapeutic and supratherapeutic doses on cardiac repolarization in healthy subjects: A thorough QT/QTc study.

Chen YC, Haznedar J, Kulkarni R, Vistuer C, Washington C, Liu M, Smith P. Chen YC, et al. Among authors: haznedar j. Clin Pharmacol Drug Dev. 2014 May;3(3):179-86. doi: 10.1002/cpdd.79. Epub 2014 Feb 6. Clin Pharmacol Drug Dev. 2014. PMID: 27128607 Clinical Trial.

9

The effect of mild to moderate renal impairment on the pharmacokinetics of the nucleoside analog hepatitis C virus polymerase inhibitor mericitabine.

Haznedar J, Moreira S, Marbury T, Robson R, Smith W, Kulkarni R, Munson ML, Thommes JA, Lemenuel-Diot A, Washington C, Smith P, Chen YC. Haznedar J, et al. Drug Dev Res. 2014 Mar;75(2):107-13. doi: 10.1002/ddr.21166. Epub 2013 Dec 26. Drug Dev Res. 2014. PMID: 24648253 Clinical Trial.

10

Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.

Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J, Kaur S, Mathews WR, Honigberg LA. Wildsmith KR, et al. Among authors: haznedar j. Mol Neurodegener. 2014 Jun 6;9:22. doi: 10.1186/1750-1326-9-22. Mol Neurodegener. 2014. PMID: 24902845 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page